BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Bank of America Merrill Lynch
|Target Hit|| Long (1Y)
Bank of America Merrill Lynch maintains buy on Aurobindo Pharma
Aurobindo Pharma has aspirations to be a $3 billion drugmaker by FY17. Actavis buy will dilute some margins. Company is doing R&D investment of $150-200 million for niche portfolio.